Key clinical point: Continuous education around molecular testing should be intensified to ensure that patients receive optimal therapy.
Major finding: A third of respondents reported being unaware of updated guidelines on molecular testing for lung cancer.
Study details: A survey of 2,537 specialists.
Disclosures: The IASLC survey was funded by AstraZeneca. Dr. Smeltzer reported receiving research support from the Bristol Myers Squibb Foundation.
Smeltzer M et al. WCLC 2019, Abstract PR01.05.